Previous studies have shown that ANXA2 overexpression is strongly associated with the progression of multiple malignancies (21–24), and promotes the metastatic potential of endometrial cancer (25, 26), kidney cancer (27, 28) and colorectal cancer (29, 30). Here, ANXA2 is linked to kidney cancer.